PUS1 and prostate carcinoma: To elucidate the degradation pathway of EIF3b, we employed inhibitors targeting these pathways, namely the ubiquitin-proteasome pathway inhibitor MG132 and the autophagy inhibitor bafilomycin (Baf), in PUS1-knockdown prostate cancer cells.